Alzheimer’s Early Warning Marker: A Breakthrough in Routine Blood Work

For years, the "holy grail" of Alzheimer’s research has been a simple, affordable way to identify who is at risk before the first signs of forgetfulness begin. On April 22, 2026, we got our answer.

A landmark study involving nearly 400,000 patients has revealed that high levels of neutrophils—the immune system's first-responder white blood cells—relative to other immune cells can signal an increased risk of Alzheimer’s and related dementias years before clinical symptoms appear

The Power of the NLR (Neutrophil-to-Lymphocyte Ratio)

The study, led by researchers at NYU Langone Health and the Veterans Health Administration, focused on a metric called the Neutrophil-to-Lymphocyte Ratio (NLR).

While doctors have used the NLR for years to track general infection and inflammation, this study is the first large-scale investigation to prove its predictive power for neurodegeneration. By analyzing electronic health records from a massive, diverse population, the team found that:

• Predictive Accuracy: An elevated NLR was independently associated with both short-term and long-term dementia risk.
  
  
• Early Detection: The elevation in neutrophils occurs long before any evidence of cognitive decline is visible on traditional tests.
  
  
• Demographic Insights: The risk associated with high NLR was notably higher for women and Hispanic patients, providing critical data for personalized health interventions.

More Than Just a Marker: Are Neutrophils the Cause?

Perhaps the most provocative finding from the research team, led by Dr. Tianshe (Mark) He and Dr. Jaime Ramos-Cejudo, is that neutrophils might not just be "bystanders."

Evidence suggests that these immune cells can cause tissue damage at the vascular level. In Alzheimer’s pathology, neutrophils have been observed accelerating disease progression by causing inflammation in the brain’s blood vessels. If neutrophils are actively contributing to the damage, they could move from being a "warning light" to becoming a direct therapeutic target—meaning we could potentially treat the inflammation to slow or stop the disease.

Infographic Breakdown: The NLR Ratio Explained

The Future: "Gateway Diagnostics"

The beauty of this discovery lies in its accessibility. Unlike expensive PET scans or invasive spinal taps, the NLR is calculated from a Complete Blood Count (CBC)—the most common blood test in the world.

"In the meantime, we hope the NLR can contribute to 'gateway diagnostic tools,'" said Dr. Ramos-Cejudo. By flagging high-risk individuals during routine check-ups, doctors can now prioritize those patients for in-depth testing and lifestyle interventions years earlier than previously possible.

Sources Used for This Blog:

• Alzheimer’s & Dementia: The Journal of the Alzheimer's Association: "Neutrophil inflammation metrics are associated with the risk of future dementia in large data from NYU Langone Hospitals and the Veterans Health Administration" (Published online April 2026).
• NYU Langone Health Press Release: "Early Immune Changes May Signal Increased Risk of Alzheimer’s & Dementia" (April 21, 2026).
• ScienceDaily / NIH News: "A simple blood test could reveal Alzheimer’s risk years early" (April 22, 2026).
• Journal Reference: He, T., et al. (2026). DOI: 10.1002/alz.71335.